A meta-analysis of profile and time-course of symptom change in acute schizophrenia treated with atypical antipsychotics

International Journal of Neuropsychopharmacology

Volumn 9, Issue 3, 2006, Pages 357-366

  Sherwood, Megan ^a,b   Thornton, Allen E ^c   Honer, William G ^a,d  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b ST PAUL S HOSPITAL   (Canada)

^c SIMON FRASER UNIVERSITY   (Canada)

^d VANCOUVER COASTAL HEALTH RESEARCH INSTITUTE   (Canada)

Author keywords

Adult; Antipsychotic agents; Clinical trials; Mental disorders; Meta analysis; Psychiatric status rating scales; Psychotic disorders; Randomized controlled trials; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ANALYSIS OF VARIANCE; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL TRIAL; DATA BASE; DECISION MAKING; DISEASE EXACERBATION; DOSE RESPONSE; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SYMPTOMATOLOGY; SYSTEMATIC REVIEW;

ACUTE DISEASE; ANTIPSYCHOTIC AGENTS; HUMANS; RANDOMIZED CONTROLLED TRIALS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TIME FACTORS;

EID: 33646878058     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145705005961     Document Type: Review

References (39)

1. Agid O, Kapur S, Arenovich T, Zipursky RB (2003). Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Archives of General Psychiatry 60, 1228-1235.
2. APA (2004). Practice Guideline for the Treatment of Patients with Schizophrenia. American Journal of Psychiatry Supplement. American Psychiatric Association.
3. Barbaran JM (2000). Intraneuronal signalling pathways. In: Sadock BJ, Sadock VA (Eds.), Kaplan & Sadock's Comprehensive Textbook of Psychiatry (7th edn), vol. 1 (pp. 78). Philadelphia: Lippincott Williams & Wilkins.
4. Beasley Jr. CM, Hamilton SH, Crawford AM, Dellva MA, Tollefson GD, Tran PV, Blin O, Beuzen JN (1997). Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. European Neuropsychopharmacology 7, 125-137.
5. Beasley Jr. CM, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S (1996). Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 14, 111-123.
6. Blin O, Azorin JM, Bouhours P (1996). Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients. Journal of Clinical Psychopharmacology 16, 38-44.
7. Borison RL, Arvanitis LA, Miller BG (1996). ICI 204,636, and atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. Journal of Clinical Psychopharmacology 16, 158-169.
8. Borison RL, Pathiraja AP, Diamond BI, Meibach RC (1992). Risperidone: clinical safety and efficacy in schizophrenia. Psychopharmacology Bulletin 28, 213-218.
9. Breier A, Schreiber J, Dyer J, Pickar D (1991). National Institute of Mental Health longitudinal study of chronic schizophrenia. Archives of General Psychiatry 48, 239-246.
10. Carone B, Harrow M, Westermeyer J (1991). Posthospital course and outcome in schizophrenia. Archives of General Psychiatry 48, 247-253.
11. Casey DE, Daniel DG, Wassef AA, Tracy KA, Wozniak P, Sommerville KW (2003). Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Neuropsychopharmacology 28, 182-192.
12. Ceskova E, Svestka J (1993). Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses. Pharmacopsychiatry 26, 121-124.
13. Conley RR, Mahmoud R (2001). A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. American Journal of Psychiatry 158, 765-774.
14. Copolov DL, Link CGG, Kowalcyk B (2000). A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, 'Seroquel') and haloperidol in schizophrenia. Psychological Medicine 30, 95-105.
15. Correll CU, Malhotra AK, Kaushik S, McMeniman M, Kane JM (2003). Early prediction of antipsychotic response in schizophrenia. American Journal of Psychiatry 160, 2063-2065.
16. Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M (1999). Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology 20, 491-505.
17. Davis JM, Chen N, Glick I (2003). A meta-analysis of the efficacy of second-generation antipsychotics. Archives of General Psychiatry 60, 553-564.
18. Fenton WS, McGlashan TH (1991). The natural history of schizophrenia subtypes: II. Positive and negative symptoms and long term course. Archives of General Psychiatry 48, 978-986.
19. Gelder M, Mayou R, Cowen P (2001). Shorter Oxford Textbook of Psychiatry. Oxford: Oxford University Press.
20. Gueorguieva R, Krystal JH (2004). Progress in analyzing repeated-measures data and its reflection in papers published in the Archives of General Psychiatry. Archives of General Psychiatry 61, 310-317.
21. Heinrichs RW, Awad AG (1993). Neurocognitive subtypes of chronic schizophrenia. Schizophrenia Research 9, 49-58.
22. Hirsch SR, Link CG, Goldstein JM, Arvanitis LA (1996). ICI 204,636: a new atypical antipsychotic drug. British Journal of Psychiatry 168 (S29), 45-56.
23. Hoyberg OJ, Fensbo C, Remvig J, Lingjaerde O, Sloth-Nielsen M, Salvesen I (1993). Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. Acta Psychiatrica Scandinavica 88, 395-402.
24. Kane JM, Carson WH, Saha AR, McQuade RM, Ingenito GG, Zimbroff DL, Ali MW (2002). Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. Journal of Clinical Psychiatry 63, 763-771.
25. Kapur S, Arenovich T, Agid O, Zipursky R, Lindborg S, Jones B (2005). Immediate onset of antipsychotic effect: the early onset hypothesis. American Journal of Psychiatry 102, 939-946.
26. Keck PE, Cohen BM, Baldessarini RJ, McElroy SL (1989). Time course of antipsychotic effects of neuroleptic drugs. American Journal of Psychiatry 146, 1289-1292.
27. Keck PJ, Buffenstien A, Ferguson J, Feighner J, Jaffe W, Harrigan EP, Morrissey MR (1998). Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology 140, 173-184.
28. King DK, Link CG, Kowalcyk B (1998). A comparison of bd and tid dose regimens of quetiapine (Seroquel) in the treatment of schizophrenia. Psychopharmacology 137, 139-146.
29. Klieser E, Lehmann E, Kinzler E, Wurthmann C, Heinrich K (1995). Randomized, double-blind, controlled trial of risperidone versus clozapine in patients with chronic schizophrenia. Journal of Clinical Psychopharmacology 15, 45S-51S.
30. Lieberman JA, Tollefson GD, Tohen M, Green AI, Gur RE, Kahn R, McEvoy J, Perkins D, Sharma T, Zipursky RB, Wei H, Hamer R (2003). Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode paychosis: a randomized, double-blind trial of olanzapine versus haloperidol. American Journal of Psychiatry 160, 1396-1404.
31. Marder SR (2000). Schizophrenia: Somatic treatment. In: Sadock BJ, Sadock VA (Eds.), Kaplan & Sadock's Comprehensive Textbook of Psychiatry (7th edn), vol. 1 (pp. 1208). Philadelphia: Lippincott Williams & Wilkins.
32. Martin S, Loo H, Peuskens J, Thirumalai S, Giudicelli A, Fleurot O, Rein W (2002). A double-blind, randomised comparative trial of amisulpiride versus olanzapine in the treatment of schizophrenia. Current Medical Research and Opinion 18, 355-362.
33. Miyamato S, Lieberman JA, Fleishhacker WW, Aoba A, Marder SR (2003). Therapeutics. In: Tasman A, Kay J, Lieberman JA (Eds.), Psychiatry (2nd edn) (pp. 2552). London: John Wiley & Sons.
34. Muller N, Riedel M, Scheppach C, Brandstatter B, Sokullu S, Krampe K, Ulmschneider M, Engel RR, Moller HJ, Schwarz MJ (2002). Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. American Journal of Psychiatry 159, 1029-1034.
35. Peuskens J, Bech P, Moller HJ, Bale R, Fleurot O, Rein W (1999). Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Psychiatry Research 88, 107-117.
36. Plesnicar BK, Zalar B, Tomori M, Kranjc I (2003). Measurement of simple reaction time in antipsychotic treatment of patients with schizophrenia. Middle European Journal of Medicine 115, 59-62.
37. Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, Stringfellow J, Ingenito G, Marder SR (2003). Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Archives of General Psychiatry 60, 681-690.
38. Sechter D, Peuskens J, Fleurot O, Rein W, Lecrubier Y (2002). Amisulpiride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study. Neuropsychopharmacology 27, 1071-1081.
39. Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CGG (1997). Quetiapine in patients with schizophrenia. Archives of General Psychiatry 54, 549-557.